4.3 Article

Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013)

Journal

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 85, Issue 2, Pages 200-204

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2016.02.009

Keywords

Candida; Aspergillus; Antifungal susceptibility; Surveillance

Funding

  1. Pfizer
  2. Astellas Pharma Global Development
  3. Achaogen
  4. Actavis
  5. Actelion
  6. Allergan
  7. American Proficiency Institute
  8. AmpliPhi
  9. Anacor
  10. Astellas
  11. AstraZeneca
  12. Basilea
  13. Bayer
  14. BD
  15. Cardeas
  16. Cellceutix
  17. CEM-102 Pharmaceuticals
  18. Cempra
  19. Cerexa
  20. Cidara
  21. Cormedix
  22. Cubist
  23. Debiopharm
  24. Dipexium
  25. Dong Wha
  26. Durata
  27. Enteris
  28. Exela
  29. Forest Research Institute
  30. Furiex
  31. Genentech
  32. GSK
  33. Helperby
  34. ICPD
  35. Janssen
  36. Lannett
  37. Longitude
  38. Medpace
  39. Meiji Seika Kasha
  40. Melinta
  41. Merck
  42. Motif
  43. Nabriva
  44. Novartis
  45. Paratek
  46. Pocared
  47. PTC Therapeutics
  48. Rempex
  49. Roche
  50. Salvat
  51. Scynexis
  52. Seachaid
  53. Shionogi
  54. Tetraphase
  55. Medicines Co.
  56. Theravance
  57. ThermoFisher
  58. VenatoRX
  59. Vertex
  60. Wockhardt
  61. Zavante

Ask authors/readers for more resources

Among 1846 fungal clinical isolates from 31 countries, echinocandin resistance in Candida spp. ranged from 0.0% to 2.8% (highest for anidulafungin versus Candida glabrata), and fluconazole resistance was noted among 11.9% and 11.6% of the C. glabrata and Candida tropicalis, respectively. Two isolates of Aspergillus fumigatus displayed elevated MICs for itraconazole and carried cyp51a mutations encoding TR34 L98H. All Cryptococcus neoformans had azole MIC values below epidemiological cutoff values. The increasing resistance among certain species and more frequent reports of breakthrough infections in patients undergoing antifungal therapy highlights the importance of antifungal surveillance to guide therapy for patients with invasive fungal infections. (C) 2016 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available